Clinical trials: Mifepristone
Abortion in Second Trimester
Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan
The primary goal is to examine the efficacy and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Uzbekistan.
- Trial name
- NCT02235155
- Where
- 3 sites in Uzbekistan
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Uterine Fibroids
Mifepristone to Treat Uterine Fibroids
Objectives: to evaluate the efficacy, safety and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9 months follow-up period.
- Trial name
- NCT01786226
- Testing
- Oral administration of mifepristone 2.5 mg daily for three months, Oral administration of mifepristone 5 mg daily for three months
- Where
- Cuba
- Volunteers
- 220 people
- Sponsor
- Mediterranea Medica S. L.
Unwanted Pregnancy
Medical Termination of II Trimester Pregnancy
The objective of this study is to compare two groups of women requiring termination of pregnancy from the gestational age of 85 days. All women will receive Mifepristone during their first visit to the out-patient ward.
- Trial name
- PRIMA (NCT03600857)
- Testing
- Home administration of misoprostol
- Where
- 4 sites in Sweden
- Volunteers
- 457 people
- Sponsor
- Karolinska Institutet
Depression
Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT
The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during…
- Trial name
- NCT00285818
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Breast Cancer
Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.
Seventy per cent of breast cancers express estrogen (ER) and progesterone receptors (PR) and respond to endocrine treatment. Actual therapy targets ER.
- Trial name
- MIPRA (NCT02651844)
- Testing
- Mifepristone
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Hospital Provincial Magdalena V. de Martínez
Prostate Cancer, Adenocarcinoma of Prostate
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.
- Trial name
- NCT00140478
- Testing
- Mifepristone
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer Female
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Investigating the potential role of a novel quadrate combination therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic acid and Cannabidiol ( selective cyp 26 inhibitor) for treating early breast cancer.
- Trial name
- NCT05016349
- Testing
- All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone
- Volunteers
- 160 people
- Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
Abortion, Induced
Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)
The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion.
- Trial name
- NCT00957346
- Testing
- Mifepristone+misoprostol
- Where
- Puerto Rico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Pregnancy Termination
Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone
A double blinded, placebo-controlled randomized trial to compare the safety, efficacy and acceptability of two medical abortion regimens up to 63 days' LMP.
- Trial name
- NCT00680394
- Testing
- mifepristone, misoprostol
- Where
- 2 sites in Tunisia, Vietnam
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Abortion, 3 Months
A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks
A pilot study on the acceptability and feasibility with Mifepristone and 400 mg of sub-lingual Misoprostol between 71-77 and 78-84 days of gestation for 50 cases.
- Trial name
- NCT02720991
- Testing
- Mifepristone, Sublingual misoprostol
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Missed Miscarriage
Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage
Miscarriage is the most common complication of pregnancy. As many as 15-25% of pregnancies end in miscarriage, and the number of miscarriages in England is estimated to be approximately 125,000 per year.
- Trial name
- MifeMiso (NCT03065660)
- Testing
- Mifepristone, Oral, 200 Mg
- Where
- 28 sites in United Kingdom
- Volunteers
- 711 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Labor, Induced
Mifepristone Outpatient Labour Induction
The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons.
- Trial name
- MOLI (NCT05177510)
- Testing
- Mifepristone
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Post-traumatic Stress Disorder
Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments
Despite substantial therapeutic advances, Posttraumatic Stress Disorder (PTSD) remains difficult to treat. One promising new area of research is in post-reactivation pharmacologic intervention, which is based upon the concept of…
- Trial name
- NCT01490697
- Testing
- Mifepristone, d-Cycloserine
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Roger K. Pitman, MD
Pregnancy
Techniques to Improve Efficacy of Second Trimester Medical Termination
Interruption of a pregnancy after 14 weeks gestation may be required when the fetus is dead, severely malformed or in cases of maternal illness.
- Trial name
- NCT00864799
- Testing
- Misoprostol
- Where
- Australia
- Volunteers
- 302 people
- Sponsor
- King Edward Memorial Hospital
Medical Abortion
Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation
To demonstrate non-inferiority of the efficacy of 200 mg mifepristone followed in 24 to 48 hours by 800 µg buccal misoprostol in outpatient medical abortion services among women 71-77 days' compared to women 64-70 days' LMP.
- Trial name
- XXGA (NCT02314754)
- Testing
- Mifepristone followed by misoprostol 24-48 hours later
- Where
- 8 sites in United States, Azerbaijan and 3 more
- Volunteers
- 719 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Non-Small Cell Lung Cancer (NSCLC)
Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This is a non-randomized, multicenter, single-stage phase II study of mifepristone in patients with advanced or metastatic NSCLC who have failed two or more previous chemotherapy regimens.
- Trial name
- NCT02642939
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Check, Jerome H., M.D., Ph.D.
Medical Abortion
Medical Abortion Self-Confirmation (MASC)
This study aims to investigate the ability of participants to perform and accurately interpret the multi-level pregnancy test and the low sensitivity pregnancy test following medication abortion, without routine provider contact.
- Trial name
- MASC (NCT03148587)
- Testing
- Self-assessment: MLPT, Self-assessment: LSPT
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Stanford University
Triple Negative Breast Neoplasms, Breast Cancer
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
This is a Phase II study of pembrolizumab plus mifepristone in advanced breast cancer patients. The study will include a safety lead in of ten patients.
- Trial name
- NCT03225547
- Testing
- Pembrolizumab, Mifepristone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Second Trimester Abortion
Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion
Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion - a Double Blinded Randomized Controlled Trial
- Trial name
- NCT03044093
- Testing
- Mifepristone, Misoprostol
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Anxiety Disorders
Medication Enhanced Rapid Therapy
The purpose of this research study is to determine whether taking a one-time dose of a combination of putatively learning-enhancing medications can improve treatment response to a brief learning-based psychotherapy for public…
- Trial name
- MERiT (NCT02099825)
- Testing
- d-cycloserine and mifepristone
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine